Literature DB >> 26780842

[How were used recommendations for endometrial carcinoma? Britain retrospective study].

O De Kerdaniel1, N Body1, E Davoine1, F Foucher2, S Henno3, A Tavenard4, B Laviolle4, C Rozel5, M Leblanc6, V Lavoué7, J Levêque8.   

Abstract

OBJECTIVE: To assess the use of French Cancer Institute recommendations for the diagnosis and treatment of endometrial cancer.
METHODS: Retrospective observational study involving 137 patients with endometrial cancer between 2011 and 2013.
RESULTS: Both MRI and pathological assessment with correct report as recommended were used for 66.4% of patients with endometrial cancer. For patients with correct preoperative assessment, 44.9% of patients were uncorrectly classified and upgraded on final pathological analysis of hysterectomy concerning lymph node involvement risk. These patients did not have confident surgical assessment, according this risk.
CONCLUSION: To improve relevance of preoperative assessment in endometrial cancer, radiological and pathological expertise is required. However, even performed optimally, preoperative assessment does not allow correct risk stratification of lymph node involvement in endometrial cancer. This ineffective stratification leads to propose sentinel lymph node biopsy with hysterectomy in case of preoperative low risk endometrial cancer assessment.
Copyright © 2016 Elsevier Masson SAS. All rights reserved.

Entities:  

Keywords:  Anatomopathologie; Cancer de l’endomètre; Endometrial cancer; IRM; MRI; Pathological analysis; Risk classification; Stratification du risque

Mesh:

Year:  2016        PMID: 26780842     DOI: 10.1016/j.jgyn.2015.12.009

Source DB:  PubMed          Journal:  J Gynecol Obstet Biol Reprod (Paris)        ISSN: 0150-9918


  1 in total

1.  [Non endometroid endometrial cancer guidelines evaluation: A multicentric retrospective study].

Authors:  Antoine Scattarelli; Albane Poteau; Moutaz Aziz; Marick Lae; Philippe Courville; Maxime Arnaud; Loic Marpeau; Benoit Resch
Journal:  Bull Cancer       Date:  2020-10-06       Impact factor: 1.276

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.